Regeneron Calls For More Government-Funding of Biologic Manufacturing While Defending High Industry Prices

COVID-19 pandemic should finally spur US government to build biologic manufacturing capacity that would be ready for emergencies, Regeneron’s top leadership says. At the same time, the company leaders said the public doesn’t appreciate the value of industry’s private investments and needs to be more accepting of medications’ price points.

Regeneron's George Yancopoulos spoke about COVID-19 and drug pricing on 18 November. • Source: STAT Summit

The US government should invest in a centralized government manufacturing facility that would be ready to quickly make biologics in the face of new health emergencies and pandemics, Regeneron Pharmaceuticals, Inc. leadership said on 18 November at the STAT Summit.

It’s an idea that was called for long before COVID-19. Regeneron’s Executive Vice President of Research and Development Neil Stahl testified about the idea to Congress in 2014 during the Ebola pandemic. The US has for some time done this for vaccines

More from Pricing Debate

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By 

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Market Access

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.